OncoMatch/Clinical Trials/NCT06920251
Phase II Trials of Letermovir Prophylaxis in Patients With RRMM Undergoing Elranatamab Therapy
Is NCT06920251 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Letermovir for relapsed refractory multiple myeloma (rrmm).
Treatment: Letermovir — This is an open-label, single arm, multicenter study to evaluate the efficacy of letermovir in the prevention of clinically significant CMV infection in adult, CMV-seropositive relapsed/refractory MM patients undergoing BsAbs therapy.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Multiple Myeloma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Must have received: proteasome inhibitor
Subject must have received at least one proteasome inhibitor
Must have received: immunomodulatory drug
Subject must have received at least one immunomodulatory drug
Must have received: anti-CD38 antibody
Subject must have received at least one anti-CD38 antibody
Cannot have received: allogeneic stem cell transplantation
Exception: allowed if >1 year prior and no active GVHD and off immunosuppressants
Subject has previously received allogeneic stem cell transplantation within a year during prior therapy. Patients who received allogeneic stem cell transplantation should not have evidence of active graft-versus-host disease (GVHD) and off any immunosuppressants.
Cannot have received: autologous stem cell transplantation
Exception: allowed if >12 weeks prior
received autologous stem cell transplantation within 12 weeks of initiating study treatment
Cannot have received: plasmapheresis
Exception: allowed if >28 days prior
Plasmapheresis within the last 28 days of initiating study treatment
Cannot have received: major surgery
Exception: allowed if >28 days prior
Major surgery (as defined by the investigator) within 28 days of initiating study treatment
Lab requirements
Blood counts
Absolute neutrophil count (ANC) < 1,000/µL; Platelet count < 25,000/µL
Kidney function
Estimated glomerular filtration rate (eGFR) < 30 mL/min or requiring dialysis
Liver function
Serum aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 2.5 × upper limit of normal (ULN); Serum total bilirubin > 1.5 × ULN, or for participants with documented Gilbert's syndrome > 3.0 mg/dL
Cardiac function
LVEF < 40% as determined by a MUGA scan or echocardiography; Prolonged QT syndrome (or QTcF >470 msec at screening); acute myocardial infarction or acute coronary syndromes within 6 months; clinically significant cardiac arrhythmias; thromboembolic or cerebrovascular events within 6 months
Absolute neutrophil count (ANC) < 1,000/µL. Platelet count < 25,000/µL. Estimated glomerular filtration rate (eGFR) < 30 mL/min or requiring dialysis. Serum aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 2.5 × upper limit of normal (ULN) Serum total bilirubin > 1.5 × ULN, or for participants with documented Gilbert's syndrome > 3.0 mg/dL. LVEF < 40% as determined by a MUGA scan or echocardiography; Prolonged QT syndrome (or QTcF >470 msec at screening); acute myocardial infarction or acute coronary syndromes within 6 months; clinically significant cardiac arrhythmias; thromboembolic or cerebrovascular events within 6 months
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06920251 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior allogeneic stem cell transplantation, autologous stem cell transplantation, plasmapheresis disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages